FDA Clears The Fenwal Amicus(R) Separator System For Collecting Platelets In New Additive SolutionFenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3)...
Source: mnt.toFDA Approves Exalgo™ Extended-Release TabletsCombinatoRx, Incorporated (NASDAQ: CRXX) announced that the U.S. Food and Drug Administration (
FDA) has approved the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time...
Source: mnt.toHealth Dialog Offers Decision Aids For Men Considering Prostate Cancer ScreeningHealth Dialog, a leading provider of healthcare analytics and decision support, today announced that its decision support tools for prostate cancer screening have been made available for the month of March as a public service offering...
Source: mnt.toFDA Clears biospace med's SterEOS 2D/3D Workstation For Pediatric Use In Spinebiospace med announced today that it has received 510(k) clearance from the
FDA (Food and Drug Administration) to market the Company's sterEOS 2D/3D workstation for pediatric use in spine applications. The Company's EOS ultra-low-dose imager previously has been
FDA-cleared for use in pediatrics and adults, while sterEOS has previously been
FDA-cleared for adult use in spine...
Source: mnt.toPlay Yourself HealthyA just published research experiment on inactive men with high blood pressure shows that just 3 months of soccer practise twice a week causes a significant fall in blood pressure, resting pulse rate, and percentage of body fat, and is more effective than the doctor's usual advice on healthy
diet and exercise...
Source: mnt.toImmunoGen, Inc. Announces Orphan Drug Designation Granted To IMGN901 For Treatment Of Merkel Cell Carcinoma By US FDA And EU COMPImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, announced that the US Food and Drug Administration (
FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC)...
Source: mnt.to
# posted by Network @ 12:31 PM
Study Reveals Potential Evolutionary Role For Same-Sex AttractionMale homosexuality doesn't make complete sense from an evolutionary point of view...
Source: mnt.toFDA, FSIS, CDC Collaborate On Methods To Measure Success Of Food Safety ProgramsThe U.S. Food and Drug Administration, the Centers for Disease Control and Prevention and the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) will host a joint public workshop on how best to measure progress in reducing foodborne illnesses on March 30, in Washington, D.C...
Source: mnt.toHearing Loss In Men Increased By Regular Analgesic UseIn a study published in the March 2010 issue of The American Journal of Medicine, researchers determined that regular use of aspirin, acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of hearing loss in men, particularly in younger men, below age 60. Hearing loss is the most common sensory disorder in the US, afflicting over 36 million people...
Source: mnt.toPoniard Pharmaceuticals Presents Positive Survival Data From A Phase 2 Clinical Study Of Picoplatin In Metastatic Prostate CancerPoniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC)...
Source: mnt.toMale Breast Reduction Fastest Growing Area Of Cosmetic Surgery In Britain Last Year The economic situation does not appear to have affected the cosmetic surgery business in Britain: new figures from a not-for-profit organisation show that the number of surgical procedures were 6.7 per cent higher in 2009 than 2008, among which the number of male breast reductions went up by 80 per cent...
Source: mnt.toProximity To Physical Activity Resources Found To Benefit Older MenA new study points to the health benefits of living in neighborhoods with built-in physical activity resources. Researchers conducted a study among community-dwelling men age 65 years or older from the Portland, Ore., metropolitan area...
Source: mnt.toMicroPhage Seeks FDA Clearance To Market World's First Test Designed To Rapidly Identify Bacterial Infections And Antibiotic SusceptibilityMicroPhage announced that it has submitted human data from a pivotal clinical study of its 'Microphage MRSA/MSSA Blood Culture Test' to support a U.S. Food and Drug Administration (
FDA) 510(k) premarket notification process. The first of MicroPhage's instrument-free, rapid tests is based on the Company's patented Bacteriophage Amplification platform technology...
Source: mnt.toGynecologic Oncology Group Notifies CTI That Continuation Of GOG-212 Pivotal Trial Of OPAXIO Maintenance Therapy In Ovarian Cancer Is A PriorityCell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue...
Source: mnt.toNovo Nordisk Receives FDA Approval For Norditropin® FlexPro® For Growth Hormone TreatmentNovo Nordisk announced today that the U.S. Food and Drug Administration (
FDA) has approved Norditropin® FlexPro® (somatropin [rDNA origin] injection), a pre-filled injection pen to be used by children and adults with growth hormone disorders. It will be available in the second quarter...
Source: mnt.to
# posted by Network @ 8:22 AM
FDA Approves Exalgo™ Extended-Release TabletsCombinatoRx, Incorporated (NASDAQ: CRXX) announced that the U.S. Food and Drug Administration (
FDA) has approved the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time...
Source: mnt.toExactech Platform Fracture Stem For Shoulder Surgeries Receives FDA ClearanceExactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration (
FDA) to market the company's Equinoxe® Platform Fracture Stem, the latest addition to the company's shoulder arthroplasty line...
Source: mnt.toNew Data From Caldolor(R) Study In Burn Patients To Be Presented At 42nd Annual Meeting Of The American Burn AssociationCumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced that data from a recent study evaluating the safety and efficacy of Caldolor® (ibuprofen) Injection in treating pain and fever in hospitalized burn patients will be presented at the 42nd Annual Meeting of the American Burn Association in Boston...
Source: mnt.toAdvanced Cell Technology's RPE Cells Granted Orphan Drug Status From FDA For Treatment Of Stargardt's Macular DystrophyAdvanced Cell Technology, Inc. (OTCBB: ACTC), a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (
FDA) has granted orphan drug designation for the company's MA09-hRPE cells for use in the treatment of Stargardt's Macular Dystrophy (SMD)...
Source: mnt.toPharmaceutical Industry Support Not Desirable But Frequently Accepted By Residency Program DirectorsMost directors of internal medicine residency training programs would prefer not to accept pharmaceutical support for the residencies they oversee, but more than half report doing so, according to an article in the February 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals...
Source: mnt.toSunridge Receives Approval For Its Non-Invasive Glaucoma Treatment In ChinaSunridge International (OTC Bulletin Board: SNDZ), announced that China's State Food and Drug Administration, (SFDA), had approved the firm's Pneumatic Trabeculoplasty (PNT) treatment in China. In making the announcement today, Sunridge International's CEO, G...
Source: mnt.toVivus's Qnexa Will Become Decision Resources' Clinical Gold Standard In 2013 For The Treatment Of ObesityDecision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus's Qnexa (the phentermine/topiramate combination) will earn Decision Resources' proprietary clinical gold standard in 2013 and through 2018 following its anticipated U.S. approval for the disease in 2011...
Source: mnt.toThree Harvard School Of Public Health Alumni Named To New FDA Tobacco Advisory CommitteeThe recently formed Food and Drug Administration (
FDA)'s Center for Tobacco Products has just created a new Tobacco Products Scientific Advisory Committee to review and evaluate safety, dependence, and health issues relating to tobacco products and provide appropriate advice, information, and recommendations to the Commissioner of Food and Drugs...
Source: mnt.toRexahn Pharmaceuticals Submits Zoraxel Phase IIb Protocol To FDARexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, announced that it has submitted a Phase IIb protocol to the
FDA for ZoraxelTM for the treatment of erectile dysfunction (ED). "The progression of Zoraxel's clinical program is very encouraging," said Rexahn Chief Executive Officer, Dr...
Source: mnt.to
# posted by Network @ 1:32 PM
